Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for ...

Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch ...

Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. (Courtesy of Dexcom) This ...

Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The ...

The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...

Cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with glucose monitoring specialist Dexcom to integrate glucose data from the Dexcom G7 into its ...